Associates Gp Llcqvt Fund V... Net Worth

The estimated Net Worth of Associates Gp Llcqvt Fund V... is at least $463 Milion dollars as of 4 June 2019. Associates V owns over 2,424,242 units of Urovant Sciences Ltd stock worth over $440,676,125 and over the last 11 years Associates sold UROV stock worth over $22,004,178.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Associates V UROV stock SEC Form 4 insiders trading

Associates has made over 13 trades of the Urovant Sciences Ltd stock since 2013, according to the Form 4 filled with the SEC. Most recently Associates bought 2,424,242 units of UROV stock worth $19,999,997 on 4 June 2019.

The largest trade Associates's ever made was buying 14,285,714 units of Urovant Sciences Ltd stock on 5 June 2018 worth over $25,000,000. On average, Associates trades about 2,569,576 units every 127 days since 2013. As of 4 June 2019 Associates still owns at least 40,765,599 units of Urovant Sciences Ltd stock.

You can see the complete history of Associates V stock trades at the bottom of the page.

What's Associates V's mailing address?

Associates's mailing address filed with the SEC is Elgin Ave, George Town, Cayman Islands.

Insiders trading at Urovant Sciences Ltd

Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... oraz Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.

What does Urovant Sciences Ltd do?

Complete history of Associates V stock trades at Agenus Inc, Arbutus Biopharma Corp, Concert Pharmaceuticals Inc, Myovant Sciences Ltd oraz Urovant Sciences Ltd

Urovant Sciences Ltd executives and stock owners

Urovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Cornelia Haag-Molkenteller,
  Chief Medical Officer of USI
• Bryan Smith,
  General Counsel - USI
• Michael McFadden,
  Chief Commercial Officer
• Christine Ocampo,
  Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
• Kenton Stewart,
  Senior Vice President of Market Access
• Walt Johnston,
  Senior Vice President of Commercial
• James Hindman,
  Director
• Shigeyuki Nishinaka,
  Director
• Ajay Bansal,
  Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer
• Myrtle Potter,
  Chairman of the Board
• James Robinson,
  Principal Executive Officer, Director
• Pierre Legault,
  Independent Director
• Sef Kurstjens,
  Independent Director
• Holdings Ltd.Dexcel Pharma ...,
  
• Associates Gp Llcqvt Fund V...,
  
• Patrick Machado,
  
• Frank Torti,
  Director
• Global Investors Lp Viking ...,
  
• Investments (Uk) Ltd Soft B...,
  
• Nori Ebersole,
  SVP&CHRO-Urovant Sciences,Inc.
• Global Performance Llc Viki...,
  
• Sciences Ltd. Roivant,
  10% owner
• Andrew Lo,
  
• Global Performance Llc Viki...,
  
• Associates Gp Llcqvt Financ...,
  
• Chemical Co., Ltd.Sumitomo ...,
  
• Keith Katkin,
  PEO;CEO/Urovant Sciences, Inc.